Revvity (RVTY) FY2024 10-K Annual Report
Revvity (RVTY) 10-K annual report for fiscal year 2024, filed with SEC EDGAR on Feb 25, 2025. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Revvity FY2024 10-K Analysis
Business Overview
- • Core business model: health science solutions delivering end-to-end workflows from discovery to diagnosis across Life Sciences and Diagnostics segments
- • New products FY 2024: BioLegend's TotalSeq™ PhenoCyte™ for scalable single-cell protein analysis; Cellometer™ Ascend automated cell counter; Phenologic.AI™ deep-learning software module
Management Discussion & Analysis
- • Revenue and profitability details not disclosed in provided section
- • No segment performance metrics available in provided text
Risk Factors
- • IRS audit and uncertain tax positions in foreign jurisdictions, with a $33.2 million increase in tax reserves in 2023
- • Ongoing foreign exchange risk, including a $24.0 million loss in 2023 cash proceeds held offshore
Revvity FY2024 Key Financial MetricsXBRL
Revenue
$2.8B
▲ +0.2% YoY
Net Income
$270M
▼ -61.0% YoY
Operating Margin
12.6%
▲ +166bp YoY
Net Margin
9.8%
▼ -1538bp YoY
ROE
3.5%
▼ -528bp YoY
Total Assets
$12.4B
▼ -8.6% YoY
EPS (Diluted)
$2.20
▼ -60.4% YoY
Operating Cash Flow
$628M
▲ +588.4% YoY
Source: XBRL data from Revvity FY2024 10-K filing on SEC EDGAR. All figures in USD.
Other Revvity Annual Reports
Get deeper insights on Revvity
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.